Cocrystal Pharma, Inc. - Form 8-K Summary
Business Context and Reporting Period
Cocrystal Pharma, Inc. (COCP), a Delaware corporation developing novel medicines for human viral diseases, filed this Current Report on Form 8-K on September 12, 2025. The report details a capital raise event that closed on September 15, 2025.
Key Financial Metrics and Transaction Details
- Gross Proceeds: Approximately $4.75 million raised upon closing.
- Registered Direct Offering: Issuance of 2,764,710 shares of Common Stock at $1.70 per share.
- Private Placement Warrants: Issuance of warrants to purchase up to 5,529,420 shares of Common Stock at an initial exercise price of $1.50 per share.
- Placement Agent Fees: H.C. Wainwright & Co., LLC received a 7.0% cash fee, a 1.0% management fee, expense reimbursement, and warrants to purchase 207,353 shares at $2.125 per share.
- Use of Proceeds: General corporate purposes and continued development of novel medicines.
Material Changes and Unusual Items
The filing represents a material change in the company's capital structure through the entry into a Securities Purchase Agreement (SPA). The transaction involved a concurrent registered direct offering and private placement. The filing text does not provide comparative financial metrics (revenue, profit, cash flow, or debt levels) for the current period versus prior periods, as this is a transaction-specific report rather than a periodic financial statement.
Guidance, Outlook, and Risks
Management intends to utilize net proceeds for general corporate purposes and the development of viral disease treatments. Key contractual obligations and risks include:
- Registration Requirement: The Company must file a Form S-1 Resale Registration Statement by October 10, 2025, and use commercially reasonable efforts to make it effective within 60 days of the closing date.
- Warrant Terms: Investor Warrants are exercisable immediately and expire 24 months after the effective date of the Resale Registration Statement. They include cashless exercise provisions and liquidated damages clauses if the Company fails to deliver shares upon valid exercise.
- Ownership Limitations: Warrant exercise is subject to a 4.99% beneficial ownership limitation (increasable to 9.99% with 61 days' notice).
Investor Verification Checklist
- Verify the final net proceeds after deducting the 8.0% total cash fees (7.0% placement + 1.0% management) and other offering expenses.
- Confirm the effective date of the Resale Registration Statement (Form S-1) to determine the exact expiration date of the Investor Warrants.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific covenants and liquidated damages calculations.
- Monitor the dilution impact of the 5,529,420 Investor Warrants and 207,353 Placement Agent Warrants if exercised.